RIPK3 is a novel prognostic marker for lower grade glioma and further enriches IDH mutational status subgrouping
ConclusionRIPK3 expression levels can be used in combination with IDH mutational status to better subgroup LGG patients regarding overall survival.
Source: Journal of Neuro-Oncology - Category: Cancer & Oncology Source Type: research
More News: Brain | Brain Tumor | Cancer | Cancer & Oncology | Colorectal Cancer | Glioma | Neurology